Recombinant Human Antibody (VRC-PG04) is capable of binding to HIV-1 gp120, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-HIV-1 gp120 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-HIV-1 gp120 mAb and CL of human light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.
Figure 1 Binding affinity constants of VRC01, VRC-PG04, and IgG b12 to core and outer domain constructs as assessed using Octet Biolayer Interferometry.
Sequential truncations of the outer domain molecule resulted in lower binding affinity while structural stabilization, mutagenesis, and glycan removal led to increased affinity for VRC01 and VRC-PG04 antibodies.
Joyce, M. G., Kanekiyo, M., Xu, L., Biertümpfel, C., Boyington, J. C., Moquin, S.,... & Zhang, B. (2013). Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.Journal of virology, 87(4), 2294-2306.
Figure 2 Surface plasmon resonance sensorgrams of VRC-PG04 antibody immobilized using an anti-Fc antibody and OD4.2.2 flowed over the respective antibody.
The black lines represent the best fit of the kinetic data to a 1:1 binding model. Experiments were carried out at 25°C in PBS buffer (pH 7.4). koff, on-rate constant (M−1s−1); kon, off-rate constant (s−1); KD, equilibrium dissociation constant.
Joyce, M. G., Kanekiyo, M., Xu, L., Biertümpfel, C., Boyington, J. C., Moquin, S.,... & Zhang, B. (2013). Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.Journal of virology, 87(4), 2294-2306.
Figure 3 Calorimetry data for the titration of OD4.2.2 with VRC-PG04 antibody in PBS buffer (pH 7.4).
Measurements were carried out in triplicate with a representative titration result shown. The top panel shows raw data with the area under each spike proportional to the heat produced at each injection of VRC-PG04 Fab. The lower panel shows integrated areas normalized to the number of moles of VRC-PG04 Fab.
Joyce, M. G., Kanekiyo, M., Xu, L., Biertümpfel, C., Boyington, J. C., Moquin, S.,... & Zhang, B. (2013). Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.Journal of virology, 87(4), 2294-2306.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
PSBL-184 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone VRC27.01); scFv Fragment | FC, Neut, FuncS | Human scFv |
PSBL-517 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone 44-VRC13.01); scFv Fragment | Neut | Human scFv |
PSBL-518 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone 45-46M2); scFv Fragment | ELISA, Neut | Human scFv |
PSBL-519 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone 45-VRC01.H5.F-185917); scFv Fragment | WB, FuncS | Human scFv |
PSBL-520 | Human Anti-HIV-1 gp120 Recombinant Antibody (clone 8ANC131); scFv Fragment | WB, FuncS | Human scFv |
There are currently no Customer reviews or questions for PABL-173. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.